Stoke Therapeutics, Inc.
STOK- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001623526
In the last 90 days, Stoke Therapeutics, Inc. insiders filed 0 open-market purchases and 6 sales; 197 institutions reported holding it in 13F filings for Q2 2026, worth $2.49B in total; no superinvestor holds it.
Q2 2025 vs. Q1 2025
How the institutions holding Stoke Therapeutics, Inc. changed between Q1 2025 and Q2 2025.
All holders in Q2 2025All holders in Q1 2025
| Measure | Q1 2025 | Q2 2025 | Change |
|---|---|---|---|
| Holders | 126 | 134 | +8 |
| Shares | 63.4M | 65.5M | +2.16M (+3.4%) |
| Value | $421.6M | $744.0M | +$322.4M (+76.5%) |
New holders (24)
Institutions that held Stoke Therapeutics, Inc. at the end of Q2 2025 but not at the end of Q1 2025.
Sold out (16)
Institutions that held Stoke Therapeutics, Inc. at the end of Q1 2025 and filed for Q2 2025 without it.
| Institution | Shares, Q1 2025 | Value, Q1 2025 |
|---|---|---|
| Checkpoint Capital L.P. | 730,717 | $4.86M |
| Renaissance Technologies LLC | 178,300 | $1.19M |
| Trexquant Investment LP | 86,140 | $572.8K |
| XTX Topco Ltd | 40,181 | $267.2K |
| Graham Capital Management, L.P. | 36,087 | $240.0K |
| Dauntless Investment Group, LLC | 28,600 | $190.2K |
| Net Worth Advisory Group | 20,741 | $137.7K |
| Mesirow Financial Investment Management, Inc. | 15,779 | $119.3K |
| Corebridge Financial, Inc. | 17,600 | $117.0K |
| Freestone Grove Partners LP | 14,776 | $98.3K |
| Axq Capital, LP | 14,600 | $97.1K |
| Fox Run Management, L.L.C. | 13,780 | $91.6K |
| Covestor Ltd | 2,417 | $16.0K |
| Coldstream Capital Management Inc | 55 | $366 |
| Parkside Financial Bank & Trust | 50 | $332 |
| Parallel Advisors, LLC | 24 | $160 |